Table 3.
Genetic testing outcomes by cohort
| FQHC | Tertiary | P** | |
|---|---|---|---|
| Number of patients | 10 | 34 | |
| Completed genetic testing, n (%) | 6 (60%) | 25 (74%) | 0.45 |
| Reason genetic testing not completed, n (%) | 0.11 | ||
| Insurance or cost considerations* | 4 (100) | 4 (44) | |
| Patient wanted time to think about it | 0 (0) | 5 (56) | |
| Type of genetic testing, n (%) | 0.36 | ||
| Multi-gene panel testing | 3 (50) | 18 (72) | |
| Single gene testing | 3 (50) | 7 (28) | |
| Type of single gene test, n (%) | |||
| BRCA1 and BRCA2 | 1 (33) | 2 (29) | |
| Lynch syndrome | 2 (67) | 0 (0) | |
| Polyposis (APC, MUTYH) | 0 (0) | 2 (29) | |
| Ashkenazi Jewish founder mutations | 0 (0) | 1 (14) | |
| Other*** | 0 (0) | 2 (29) | |
| Mutation identified, n (%) | 0 (0) | 5 (20) | 0.55 |
| Gene, n | |||
| BRCA1 | 0 | 1 | |
| Lynch (MLH1 (2), PMS2 (1)) | 0 | 3 | |
| CHEK2 | 0 | 1 | |
| Variant of unknown significance identified, n (%) | 2 (33) | 6 (24) | 0.63 |
| Gene, n | |||
| BRCA1 | 0 | 1 | |
| BRCA2 | 1 | 0 | |
| BRIP1 | 1 | 0 | |
| MLH1 | 0 | 1 | |
| MSH2 | 0 | 1 | |
| NBN | 0 | 1 | |
| NF1 | 0 | 2 | |
*FQHC patients: Medicaid (N = 2), Medicare (N = 1), private (N = 1); DFCI patients: Medicare (N = 2), private (N = 2)
**P values are calculated by Fisher’s exact test
***Other is noted for patients who had two single gene tests (i.e., polyposis and Lynch syndrome)